Genredigerande läkemedel sänker det onda kolesterolet med 62 procent i studie

En experimentell terapi vid namn VERVE-102 sänkte LDL-kolesterolet med upp till 62 procent efter en enstaka dos i en tidig säkerhetsstudie. Resultaten kommer från en fas I-studie med 35 patienter som lider av högt kolesterol eller tidig hjärt-kärlsjukdom. Data publicerades denna vecka i New England Journal of Medicine.

Forskare rapporterade att behandlingen verkade säker, utan några allvarliga biverkningar ens vid den högsta dosen. Deltagarna upplevde endast en tillfällig mild ökning av leverenzymer. Läkemedlet använder mRNA förpackat i nanopartiklar för att redigera PCSK9-genen i leverceller, vilket permanent minskar produktionen av ett protein som höjer LDL-nivåerna.

Relaterade artiklar

Scientific illustration of HELZ2 protein in the liver regulating cholesterol release.
Bild genererad av AI

UT Southwestern researchers identify HELZ2 protein that controls the liver’s release of cholesterol-carrying particles

Rapporterad av AI Bild genererad av AI Faktagranskad

Scientists at UT Southwestern Medical Center report they have identified a protein, HELZ2, that acts as a key regulator of how many cholesterol-carrying particles the liver releases into the bloodstream by affecting the gene APOB. The study was published in the American Heart Association journal Circulation and could inform future research into heart disease and fatty liver disease.

Researchers from the University of Barcelona and the University of Oregon report that short DNA molecules known as polypurine reverse Hoogsteen hairpins (PPRHs) suppressed the PCSK9 gene and reduced blood cholesterol in a mouse model. In transgenic mice carrying the human PCSK9 gene, a single injection of one candidate (HpE12) cut plasma PCSK9 by 50% and total cholesterol by 47% three days later, according to findings published in Biochemical Pharmacology.

Rapporterad av AI

A new study indicates that measuring apolipoprotein B could help prevent more heart attacks and strokes than the standard LDL cholesterol test used by millions of Americans.

A single mRNA injection can halve the rate of chromosome errors in human eggs from older women, according to new research presented at a London conference. The treatment targets a protein deficiency that contributes to aneuploidy, a common cause of IVF failure and miscarriage. Researchers say the approach shows promise for improving fertility outcomes.

Rapporterad av AI Faktagranskad

Researchers from the Institute for Bioengineering of Catalonia and collaborating institutions report that engineered “supramolecular” nanoparticles restored aspects of blood-brain barrier function in Alzheimer’s-model mice, rapidly lowering brain amyloid-β and producing improvements on behavioral and memory tests.

Denna webbplats använder cookies

Vi använder cookies för analys för att förbättra vår webbplats. Läs vår integritetspolicy för mer information.
Avböj